📊 AMRX Key Takeaways
Is Amneal Pharmaceuticals, Inc. (AMRX) a Good Investment?
Amneal demonstrates solid operational performance with 8% revenue growth and positive free cash flow generation ($269.9M), but the negative stockholders' equity (-$70.8M) and high debt burden ($2.6B) create significant financial distress despite adequate liquidity. The company's thin net margin (2.4%) and weak return on assets (2.0%) suggest limited earnings power relative to its asset base and debt obligations.
Amneal shows improving operating fundamentals, with 8.0% revenue growth, solid 13.1% operating margin, and healthy free cash flow generation of $269.93M. However, the balance sheet remains a major constraint due to negative stockholders' equity and $2.57B of long-term debt, while net profitability is still thin at a 2.4% margin. The business appears operationally stronger, but financial risk limits conviction until leverage and bottom-line durability improve further.
Why Buy Amneal Pharmaceuticals, Inc. Stock? AMRX Key Strengths
- Positive revenue growth of 8% YoY with $3.0B in total revenues
- Strong free cash flow generation of $269.9M with 8.9% FCF margin
- Adequate liquidity position with 2.17x current ratio and $282.0M in cash
- Improving diluted EPS (+157.9% YoY) indicating potential earnings leverage
- Revenue growth is solid and appears supported by positive operating leverage, with operating income reaching $394.10M.
- Cash generation is healthy, with $339.99M in operating cash flow and an 8.9% free cash flow margin.
- Liquidity is adequate, with a 2.17x current ratio and 1.48x quick ratio providing near-term balance sheet flexibility.
AMRX Stock Risks: Amneal Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$70.8M indicates balance sheet insolvency risk
- High debt burden of $2.6B relative to net income and equity cushion
- Very low net profit margin of 2.4% limits financial flexibility and debt servicing capacity
- Operating leverage risk with thin margins vulnerable to revenue or cost disruptions
- Limited asset efficiency (2.0% ROA) raises questions about capital productivity
- Negative stockholders' equity indicates a stressed capital structure and makes balance sheet quality weak despite positive earnings.
- Long-term debt of $2.57B is high relative to the company's asset base and increases refinancing and interest burden risk.
- Net margin remains low at 2.4%, so modest operating setbacks could materially pressure earnings quality.
Key Metrics to Watch
- Debt reduction trajectory and leverage ratios (debt-to-EBITDA)
- Operating cash flow sustainability and free cash flow trend
- Gross and operating margin expansion or contraction
- Quarterly revenue growth consistency and product mix
- Equity recovery path and working capital efficiency
- Net debt reduction and any improvement in stockholders' equity
- Sustained free cash flow and expansion in net margin
Amneal Pharmaceuticals, Inc. (AMRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.17x current ratio provides a solid financial cushion.
AMRX Profit Margin, ROE & Profitability Analysis
AMRX vs Healthcare Sector: How Amneal Pharmaceuticals, Inc. Compares
How Amneal Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amneal Pharmaceuticals, Inc. Stock Overvalued? AMRX Valuation Analysis 2026
Based on fundamental analysis, Amneal Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amneal Pharmaceuticals, Inc. Balance Sheet: AMRX Debt, Cash & Liquidity
AMRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amneal Pharmaceuticals, Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
AMRX Revenue Growth, EPS Growth & YoY Performance
AMRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $702.5M | -$156.0K | $0.00 |
| Q2 2025 | $701.8M | $6.0M | $0.02 |
| Q1 2025 | $659.2M | $12.2M | $0.04 |
| Q3 2024 | $620.0M | -$156.0K | $0.00 |
| Q2 2024 | $599.0M | $5.0M | $0.02 |
| Q1 2024 | $557.5M | -$6.9M | $-0.05 |
| Q3 2023 | $545.6M | -$7.6M | $-0.02 |
| Q2 2023 | $559.4M | $6.6M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amneal Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AMRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amneal Pharmaceuticals, Inc. (CIK: 0001723128)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMRX
What is the AI rating for AMRX?
Amneal Pharmaceuticals, Inc. (AMRX) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMRX's key strengths?
Claude: Positive revenue growth of 8% YoY with $3.0B in total revenues. Strong free cash flow generation of $269.9M with 8.9% FCF margin. ChatGPT: Revenue growth is solid and appears supported by positive operating leverage, with operating income reaching $394.10M.. Cash generation is healthy, with $339.99M in operating cash flow and an 8.9% free cash flow margin..
What are the risks of investing in AMRX?
Claude: Negative stockholders' equity of -$70.8M indicates balance sheet insolvency risk. High debt burden of $2.6B relative to net income and equity cushion. ChatGPT: Negative stockholders' equity indicates a stressed capital structure and makes balance sheet quality weak despite positive earnings.. Long-term debt of $2.57B is high relative to the company's asset base and increases refinancing and interest burden risk..
What is AMRX's revenue and growth?
Amneal Pharmaceuticals, Inc. reported revenue of $3.0B.
Does AMRX pay dividends?
Amneal Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AMRX SEC filings?
Official SEC filings for Amneal Pharmaceuticals, Inc. (CIK: 0001723128) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMRX's EPS?
Amneal Pharmaceuticals, Inc. has a diluted EPS of $0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Amneal Pharmaceuticals, Inc. has a HOLD rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AMRX stock overvalued or undervalued?
Valuation metrics for AMRX: ROE of N/A (sector avg: 15%), net margin of 2.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMRX stock in 2026?
Our dual AI analysis gives Amneal Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMRX's free cash flow?
Amneal Pharmaceuticals, Inc.'s operating cash flow is $340.0M, with capital expenditures of $70.1M. FCF margin is 8.9%.
How does AMRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.17 (avg: 2).